Ascendis Pharma A/S
ASND
65 hedge funds and large institutions have $1.22B invested in Ascendis Pharma A/S in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 12 closing their positions.
166% more capital inflows, than outflows
Capital inflows: $106M | Capital outflows: $39.9M
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
12% more funds holding
Funds holding: 58 → 65 (+7)
3.19% more ownership
Funds ownership: 50.46% → 53.65% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.5M |
| 2 |
BlackRock
New York
|
+$15.7M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.9M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$9.8M |
| 5 |
Eventide Asset Management
Boston,
Massachusetts
|
+$4.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Laurion Capital Management
New York
|
-$8.3M |
| 2 |
JP Morgan Chase
New York
|
-$7.16M |
| 3 |
VMI
VHCP Management II
New York
|
-$6.76M |
| 4 |
Driehaus Capital Management
Chicago,
Illinois
|
-$3.6M |
| 5 |
Marshall Wace North America
New York
|
-$3.21M |
ASND Hedge Fund Activity: Q4 2017 in Review
65 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2017, worth a combined $1.22B — up 17% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ASND positions and 12 closed out — a net gain of 7 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $16.5M. The largest seller was Laurion Capital Management, cutting an estimated $8.3M.
- 65 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2017, up from 58 in Q3 2017.
- Funds reported $1.22B of Ascendis Pharma A/S stock for Q4 2017, up 17% quarter-over-quarter.
- 19 funds opened new Ascendis Pharma A/S positions in Q4 2017 and 12 closed out, a net change of +7 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2017 was T. Rowe Price Associates, an estimated $16.5M added.
- The largest Ascendis Pharma A/S seller in Q4 2017 was Laurion Capital Management, an estimated $8.3M sold.
Based on aggregated 13F filings for Q4 2017.